When you linking your Twitter Account Market Wire News Trending Stocks news and your Portfolio Stocks News will automatically tweet from your Twitter account.
Be alerted of any news about your stocks and see what other stocks are trending.
MYOK - MyoKardia's mavacamten shows sustained benefit in extension study
MyoKardia Inc.
Results from an open-label extension study from the Phase 2 PIONEER-HCM trial evaluating MyoKardia's (MYOK-0.2%) mavacamten in patients with symptomatic obstructive hypertrophic cardiomyopathy (HCM) showed a durable treatment effect through week 36. The data were presented at the ESC Congress in Paris.
More news on: MyoKardia, Inc., Healthcare stocks news,